DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

Size: px
Start display at page:

Download "DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran."

Transcription

1 Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/ Introduction This guideline is for the clinical management of patients on direct oral anticoagulants (DOACs) with a hip fracture in whom surgery is being considered. 2. Scope This guideline applies only to patients with a hip fracture who are on direct oral anticoagulants, a class of drug which includes Rivaroxaban, Apixaban, Edoxaban and Dabigatran. 3. Recommendations, Standards and Procedural Statements DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran. Immediate management: Pre-operative phase Stop DOAC Document time and amount of last dose taken Document indication for anticoagulation and thrombotic risk (see attached thrombotic risk assessment tool appendices 1,2) Establish IV access and ensure adequate hydration, oxygenation and blood pressure maintenance Send urgent samples for FBC, U&E, LFT, G&S, clotting screen (PT, APTT and TT) and fibrinogen PRINT AND COMMENCE AUDIT RECORD (APPENDIX 1) AND FILE IN MEDICAL NOTES Follow advice below according to DOAC type Page 1 of 12

2 Dabigatran Contact Haemostasis team (weekdays 9-5) or on-call Haematology Registrar for Agreement to give reversal agent Idarucizumab (Praxbind) (to be administered by anaesthetist, and only indicated if TT is prolonged see notes below) Peri-operative bridging plan in high risk or unstable patients (see appendices 1,2) Proceed to surgery following discussion between surgery, anaesthesia, orthogeriatrics, haematology, and patient. Notes: i. A normal thrombin time (TT) rules out clinically significant plasma concentration of Dabigatran. In this case do not give Praxbind. ii. Prolonged TT only indicates presence of Dabigatran but gives no indication as to the degree of anticoagulation. iii. Prolonged TT, normal APTT suggests very minimal plasma concentration of Dabigatran. Surgery probably safe from an anticoagulant perspective. Discuss with haematology. iv. Praxbind should be given by an anaesthetist in theatre as there is a small risk of severe allergic / anaphylactic reaction. It is given intravenously as 2 consecutive infusions of 2.5g/50 ml, each over 5 to 10 minutes. If infused through a pre-existing IV line, this must be flushed with 0.9% sodium chloride before and after the infusion. Rivaroxaban / Apixaban If ingested within 2 hours give activated charcoal (available in ED). If PT > 20 seconds, Rivaroxaban level likely to be > 100 ng/ml PT > 40 seconds is unlikely to be solely due to Rivaroxaban or Apixaban. CONSIDER OTHER ANTICOAGULANT EFFECT OR OTHER CAUSE OF PT PROLONGATION. Please note that PT cut-off values suggested above are valid ONLY with our current PT reagent, Neoplastine CI Plus. Values may alter with change of reagent. Contact Haemostasis team (weekdays 9am-5pm) or on-call Haematology Registrar to Seek agreement to perform drug specific Anti-Xa assays Discuss peri-operative bridging plan in high risk or unstable patients (see appendices 1,2). Page 2 of 12

3 Ordering DOAC Levels To request Rivaroxaban or Apixaban specific Anti-Xa assay for drug specific plasma concentration: Take two citrated samples (green topped bottles) filled to the mark and transport by hand to Special Haematology laboratory (extension 6619), Level 2 Sandringham Building, Leicester Royal Infirmary. Do not send samples via hospital chute system. Tests should be done near to the time of surgery (e.g. in the morning for proposed afternoon surgery). Lab staff are on site Monday Friday, and Saturday mornings, and are on-call outside these hours. Interpretation of Plasma Levels DOAC PLASMA CONCENTRATION ACTIONS, ASSUMING ALL HIP FRACTURE SURGERY HAS HIGH BLEEDING RISK < 30 ng / L Proceed With Surgery Multi Disciplinary Assessment of Risk vs Benefit of surgery (Anaesthesia, Orthopaedics, Orthogeriatrics, Haematology) Ensure Hydration Monitor Fluid Balance ng / L Consider Octaplex (Prothrombin Complex Concentrate) 20 units /kg (can be repeated up to total dose 50 iu/kg: discuss with haematology). Please note that PCC is NOT a specific reversal agent for DOACs. Consider Repeating Anti-Xa assay after 12 hours Avoid neuraxial anaesthesia ng / L Delay surgery by a minimum of 24 hours. Ensure hydration and monitor fluid balance. Repeat anti-xa assay after 24 hrs, and then every 12 hrs Page 3 of 12

4 Intra-operative Management of Patients with Residual DOAC Effect Consultant Surgeon and Consultant Anaesthetist to do case Give tranexamic acid 1g IV unless contraindicated (known sensitivity to tranexamic acid, arterial or venous thrombosis within the last 3 months, history of epilepsy / seizures or significantly impaired renal function {avoid where CrCl<20, lower dose of 10 mg/kg if CrCl 20-30, 1g if CrCl >30}). If subsequent doses required use 10mg/kg IV OR 0.5-1g IV TDS. Consider intra-operative cell salvage Ensure cross matched blood available Maintain Hb > 80 (> 90 if cardiovascular disease) Consider Intraoperative Prothrombin Complex Concentrate (Octaplex) Consider Use of TEG (note currently no data to support use of TEG in patients on DOAC) Fill in audit form and keep in medical notes Post-Operative Management Check FBC and U&E day 1 post surgery Restart DOAC after hours providing bleeding risk low. Give standard prophylaxis with LMWH Follow bridging plan where recommended by Haemostasis & Thrombosis team Complete audit form before discharge and give to Trauma Scheduler for analysis by Audit Lead Page 4 of 12

5 4. Education and Training Training on use of the guideline will comprise awareness training, including awareness of thrombotic risk assessment and perioperative management of anticoagulated patients, and training for audit data collection. 5. Monitoring and Audit Criteria Data to be collected according to audit tool in appendix Legal Liability Guideline Statement See section 6.4 of the UHL Policy for Policies for details of the Trust Legal Liability statement for Guidance documents 7. Supporting Documents and Key References If applicable 8. Key Words DOAC, NOAC, Rivaroxaban, Apixaban, Dabigatran, Praxbind, Idarucizumab Page 5 of 12

6 Appendix 1 Risk of thrombo-embolism risk assessment tool: NON-VALVULAR ATRIAL FIBRILLATION VENOUS THROMBO- EMBOLISM (DVT/PE) MECHANICAL PROSTHETIC HEART VALVE OTHER DISCUSS WITH HAEMATOLOGY (HIGH RISK) 1. Previous TIA/stroke HIGH THROMBOEMBOLIC RISK (BRIDGING WITH THERAPEUTIC ANTICOAGULATION REQUIRED) 2. CHA 2 DS 2 VASC* 6 DVT or PE < 3 months. DVT/PE with target INR Antiphospholipid syndrome All Mitral Aortic + risk factors* *atrial fibrillation, CCF, age > 75y, diabetes, increased fibrinogen levels, LV dysfunction, left atrial dilatation (diameter >50mm Atrial fibrillation with mitral stenosis Antiphospholipid syndrome Antithrombin deficiency History of Heparin induced thrombocytopenia (HIT) or Heparin allergy LOW THROMBOEMBOLIC RISK (PROPHYLACTIC LMWH REQUIRED ONLY FOR VTE THROMBOPROHYLAXIS AS NEEDED) 1.No previous TIA/Stroke 2. CHA 2 DS 2 VASC* < 6 DVT or PE > 3 months Aortic: no cardiovascular risk factors Page 6 of 12

7 Stroke risk stratification in Atrial Fibrillation: CHA 2 DS 2 VASC Appendix 2 Use this risk calculator for patients with atrial fibrillation to estimate cardioembolic risk RISK FACTOR CHA 2 DS 2 VASC SCORE Congestive heart failure 1 Hypertension 1 Age Diabetes mellitus 1 Stroke/TIA/systemic 2 thromboembolism Vascular disease 1 Age 75 2 Sex Category (Female) 1 Page 7 of 12

8 Appendix3. Audit Data Collection DOAC AUDIT TOOL S number Time / Date of arrival (or referral if in-patient) DOAC / Indication Dose / time of last dose Praxbind yes / no / time DOAC levels yes / no / time / results / action Time to theatre Tranexamic Acid y / n / time / dose Estimated intraoperative blood loss Transfusion during admission yes / no / time / amount Reasons for delay to theatre > 36 hours Comments Page 8 of 12

9 This table is used to track the development and approval and dissemination of the document and any changes made on revised / reviewed versions Author / Lead Officer: Reviewed by: Approved by: Date DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT Dorothea Morfey Job Title: Consultant Anaesthetist MSS Quality and Safety Board Issue Number Reviewed By REVIEW RECORD Date Approved: December 2016 Description Of Changes (If Any) DISTRIBUTION RECORD: Date Name Dept Received Page 9 of 12

10 Page 10 of 12

11 Page 11 of 12

12 Page 12 of 12

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.

More information

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents

Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist

More information

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS

GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol

More information

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or

More information

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins

Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity

More information

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients

4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients 4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk

More information

Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension Direct Line tadamson(anhs.

Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension Direct Line tadamson(anhs. NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 th March 2018 Our Ref FA_Anticoag/MGPG/Mar18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224 556689

More information

Do s and Don t of DOACs DISCLOSURE

Do s and Don t of DOACs DISCLOSURE Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier

More information

Appendix 3 PCC Warfarin Reversal

Appendix 3 PCC Warfarin Reversal Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin

More information

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17 2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical

More information

Title Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines. Department.

Title Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines. Department. Document Control Title Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines Author Author s job title Pharmacist Directorate PCS - Department Version

More information

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical

More information

North East Essex Medicines Management Committee

North East Essex Medicines Management Committee Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES

More information

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October

More information

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get

More information

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in

More information

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR

MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma

More information

Managing Perioperative Anticoagulation. Edie Shen MD

Managing Perioperative Anticoagulation. Edie Shen MD Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)

More information

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review

More information

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults

More information

New Age Anticoagulants: Bleeding Considerations

New Age Anticoagulants: Bleeding Considerations Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University

More information

surgery and procedures.

surgery and procedures. Anticoagulation bridging therapy for elective surgery and procedures. surgery and procedures. 1. Introduction 1.1 This suite of guidelines covers the management of elective patients taking anticoagulant

More information

Joost van Veen Consultant Haematologist

Joost van Veen Consultant Haematologist Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative

More information

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic

More information

Anticoagulation bridging therapy for elective surgery and procedures.

Anticoagulation bridging therapy for elective surgery and procedures. Anticoagulation bridging therapy for elective surgery and procedures. 1. Introduction 1.1 This suite of guidelines covers the management of elective patients taking anticoagulant medication who need to

More information

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:

Active date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions: Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

DEEP VEIN THROMBOSIS (DVT): TREATMENT

DEEP VEIN THROMBOSIS (DVT): TREATMENT DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada

More information

Reversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier

Reversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Coagulation, Haemostasis and interpretation of Coagulation tests

Coagulation, Haemostasis and interpretation of Coagulation tests Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect

More information

WARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES

WARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES WARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances

More information

Comparison of novel oral anticoagulants (NOACs)

Comparison of novel oral anticoagulants (NOACs) Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics

Anticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives

More information

Challenges in Coagulation

Challenges in Coagulation Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

Haematology Subcommittee of PTAC Meeting held 16 March 2016

Haematology Subcommittee of PTAC Meeting held 16 March 2016 Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information

More information

Pathology Service User Guide Haematology

Pathology Service User Guide Haematology Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT

DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC

More information

Direct Oral Anticoagulant Reversal

Direct Oral Anticoagulant Reversal 08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics

More information

The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015

The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi

More information

Author (include and role): Division & Speciality: CAS (Haematology) Version: 1 Ratified by: DTC Scope (Target audience, state if Trust wide):

Author (include  and role): Division & Speciality: CAS (Haematology) Version: 1 Ratified by: DTC Scope (Target audience, state if Trust wide): Full Title of Guideline: Author (include email and role): Guidelines for the management of adult patients taking Direct Oral Anticoagulants (DOACs) who require elective, non-cardiac non-neurosurgical procedures

More information

COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS

COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS SOPHIE TESTA Haemostasis and Thrombosis Center ASST-Cremona, Italy ANTICOAGULANT DRUGS Eikelboom JW, Weitz JI. Circulation 2010;6:1523-32 DRUGS UH LAB aptt

More information

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

Perioperative Management of Anticoagulation

Perioperative Management of Anticoagulation Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

Perioperative Management of the Anticoagulated Patient

Perioperative Management of the Anticoagulated Patient Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center

More information

Southern Trust Anticoagulant Team

Southern Trust Anticoagulant Team CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date: Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Anticoagulants: Agents, Pharmacology and Reversal

Anticoagulants: Agents, Pharmacology and Reversal Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

a. A pharmacist may order a baseline SCr per protocol

a. A pharmacist may order a baseline SCr per protocol UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal) (including reversal) A Clinical Guideline recommended for use: In: By: For: Key words: Written by: All Clinical Areas All medical and nursing staff Adult patients requiring anticoagulation with warfarin

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

Obesity, renal failure, HIT: which anticoagulant to use?

Obesity, renal failure, HIT: which anticoagulant to use? Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have

More information

Misunderstandings of Venous thromboembolism prophylaxis

Misunderstandings of Venous thromboembolism prophylaxis Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario

More information

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN

More information

Chapter 1 The Reversing Agents

Chapter 1 The Reversing Agents Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships

More information

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis

More information

2.5 Other Hematology Consult:

2.5 Other Hematology Consult: The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR

More information

Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January

More information

NOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB

NOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the

More information

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million

More information

Choosing and Managing Direct Oral Anticoagulants (DOACs)

Choosing and Managing Direct Oral Anticoagulants (DOACs) Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline

More information

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines.

t. Recommendations for periprocedural anticoagulation are available lhrough the American College of Chest Physicians Clinical Practice Guidelines. Name or Policy: Policy Number: 3364-133-116 Department: Approving Officer: Responsible Agent: cope: x Management of Anticoagulation with Invasive Procedures Pharmacy Chief Operating Officer Director of

More information

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY

ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START

More information

Reversal of anticoagulation in GI Bleeding

Reversal of anticoagulation in GI Bleeding Blood and Guts Reversal of anticoagulation in GI Bleeding John Hanley Consultant Haematologist Newcastle Hospitals NHS Trust john.hanley@nuth.nhs.uk Healthy situation Haemostatic seesaw in a happy balance

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Reversal of Anticoagulants at UCDMC

Reversal of Anticoagulants at UCDMC Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant

More information

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)

Trust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal) (including reversal) A Clinical Guideline recommended for use: For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author

More information

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management

More information

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most

More information

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

Feedback from the EMA

Feedback from the EMA Feedback from the EMA Jens Heisterberg, MD Danish Medicines Agency Is There a Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? CSRC Meeting, Washington D.C., December 3,

More information

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology

Novel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug

More information

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List

More information

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole

More information

Oral anti-thrombotic therapy-management in patients requiring endoscopy

Oral anti-thrombotic therapy-management in patients requiring endoscopy Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients

More information

DIRECT ORAL ANTICOAGULANTS

DIRECT ORAL ANTICOAGULANTS 2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral

More information

Guidelines for the management of warfarin reversal in adults

Guidelines for the management of warfarin reversal in adults SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central

More information

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI 10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:

More information